M G Peters

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
    M G Peters
    University of California at San Francisco, 94143, USA
    Transplantation 68:1912-4. 1999
  2. ncbi Animal models of autoimmune liver disease
    Marion G Peters
    Division of Gastroenterology, University of California, San Francisco, California 94143 0538, USA
    Immunol Cell Biol 80:113-6. 2002
  3. ncbi Alcohol use and hepatitis C
    Marion G Peters
    Department of Gastroenterology, University of California, San Francisco, CA 94143, USA
    Hepatology 36:S220-5. 2002
  4. ncbi Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B
    Marion G Peters
    Division of Gastroenterology, University of California, San Francisco, CA 94143, USA
    Gastroenterology 126:91-101. 2004
  5. ncbi Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis
    Debika Bhattacharya
    University of California, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 55:170-5. 2010
  6. ncbi Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States
    Marion G Peters
    University of California at San Francisco, San Francisco, CA 94143 0538, USA
    Hepatology 46:769-75. 2007
  7. ncbi Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects
    Caroline M Behler
    Department of Hematology and Oncology, University of California San Francisco, San Francisco, CA 94143 1270, USA
    Clin Infect Dis 44:1375-83. 2007
  8. ncbi Viral hepatitis in HIV infection
    Margaret James Koziel
    Division of Infectious Disease, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 356:1445-54. 2007
  9. ncbi Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127
    Marion G Peters
    University of California, San Francisco, San Francisco, CA, USA
    Hepatology 44:1110-6. 2006
  10. ncbi Influence of cannabis use on severity of hepatitis C disease
    Julie H Ishida
    Department of Medicine, University of California at San Francisco, San Francisco, California, USA
    Clin Gastroenterol Hepatol 6:69-75. 2008

Collaborators

Detail Information

Publications25

  1. ncbi Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
    M G Peters
    University of California at San Francisco, 94143, USA
    Transplantation 68:1912-4. 1999
    ..Mutations in the hepatitis B virus (HBV) genome may occur during therapy...
  2. ncbi Animal models of autoimmune liver disease
    Marion G Peters
    Division of Gastroenterology, University of California, San Francisco, California 94143 0538, USA
    Immunol Cell Biol 80:113-6. 2002
    ..The plethora of antigens implicated in autoimmune hepatitis in humans predicts that multiple mechanisms may play a role in precipitating disease in the susceptible individual...
  3. ncbi Alcohol use and hepatitis C
    Marion G Peters
    Department of Gastroenterology, University of California, San Francisco, CA 94143, USA
    Hepatology 36:S220-5. 2002
    ..The literature is inadequate to provide definitive recommendations regarding the effect of light to moderate alcohol use in patients with hepatitis C...
  4. ncbi Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B
    Marion G Peters
    Division of Gastroenterology, University of California, San Francisco, CA 94143, USA
    Gastroenterology 126:91-101. 2004
    ....
  5. ncbi Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis
    Debika Bhattacharya
    University of California, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 55:170-5. 2010
    ..In HIV/ hepatitis C virus (HCV) coinfection, adverse events (AEs) during HCV therapy account for 12%-39% of treatment discontinuations. It is unknown whether sex influences complications...
  6. ncbi Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States
    Marion G Peters
    University of California at San Francisco, San Francisco, CA 94143 0538, USA
    Hepatology 46:769-75. 2007
    ..Possible mechanisms underlying this health discrepancy are not clear, but increased awareness of PBC as a cause of chronic cholestatic liver disease is critical in evaluating non-Caucasian patients in the United States...
  7. ncbi Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects
    Caroline M Behler
    Department of Hematology and Oncology, University of California San Francisco, San Francisco, CA 94143 1270, USA
    Clin Infect Dis 44:1375-83. 2007
    ....
  8. ncbi Viral hepatitis in HIV infection
    Margaret James Koziel
    Division of Infectious Disease, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 356:1445-54. 2007
  9. ncbi Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127
    Marion G Peters
    University of California, San Francisco, San Francisco, CA, USA
    Hepatology 44:1110-6. 2006
    ..In conclusion, over 48 weeks, treatment with either ADV or TDF resulted in clinically important suppression of serum HBV DNA. Both drugs are safe and efficacious for patients coinfected with HBV and HIV...
  10. ncbi Influence of cannabis use on severity of hepatitis C disease
    Julie H Ishida
    Department of Medicine, University of California at San Francisco, San Francisco, California, USA
    Clin Gastroenterol Hepatol 6:69-75. 2008
    ..Complications of HCV infection are primarily related to the development of advanced fibrosis and whether cannabis use is a risk factor for more severe fibrosis is controversial...
  11. ncbi Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis
    Burton Combes
    The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9151, USA
    Hepatology 42:1184-93. 2005
    ..In conclusion, methotrexate when added to UDCA for a median period of 7.6 years had no effect on the course of PBC treated with UDCA alone...
  12. ncbi Managing hepatitis B coinfection in HIV-infected patients
    Marion G Peters
    Division of Gastroenterology, Box 0538, University of California, 513 Parnassus Ave, Room S 357, San Francisco, CA 94143 0538, USA
    Curr HIV/AIDS Rep 2:122-6. 2005
    ..Long-term management of hepatitis B includes monitoring for hepatocellular carcinoma. Two recent consensus conferences have provided excellent reviews of management of coinfection ...
  13. ncbi Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients
    Kenneth E Sherman
    Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Gastroenterology 128:313-27. 2005
    ..HCV-monoinfected patients. Reasons for this remain unclear. This study evaluated kinetic parameters and treatment responses in co-infected vs monoinfected patients...
  14. ncbi Antiviral therapy: nucleotide and nucleoside analogs
    David J Quan
    Department of Clinical Pharmacy, University of California, San Francisco, 521 Parnassus Avenue, Room C-152, Box 0622, San Francisco, CA 94143-0622, USA
    Clin Liver Dis 8:371-85. 2004
    ..Other nucleoside analogs are in various stages of development, including MCC-478 and DAPD. In the future, clinicians will have a plethora of reagents to chose from, and combination therapies may be invoked...
  15. ncbi Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
    Raymond T Chung
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 351:451-9. 2004
    ..We conducted a multicenter, randomized trial comparing peginterferon plus ribavirin with interferon plus ribavirin for the treatment of chronic hepatitis C in persons coinfected with HIV...
  16. ncbi The challenge of diagnosing autoimmune hepatitis: less is more
    Gina Choi
    Hepatology 48:10-2. 2008
  17. ncbi Diagnosis and management of hepatitis B virus and HIV coinfection
    Marion G Peters
    Hepatology Research, University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 15:163-6. 2007
    ..This article summarizes a presentation on HIV and HBV coinfection made by Marion G. Peters, MD, at an International AIDS Society-USA Continuing Medical Education course in San Francisco in May 2007...
  18. ncbi Role of alphavbeta6 integrin in acute biliary fibrosis
    Bruce Wang
    Liver Center, Department of Medicine, University of California, San Francisco, USA
    Hepatology 46:1404-12. 2007
    ..The findings provide a rationale for the use of inhibitors of alphavbeta6 integrin or TGFbeta for down-regulating fibrosis in the setting of acute or ongoing biliary injury...
  19. ncbi Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis
    Burton Combes
    University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9151, USA
    Am J Gastroenterol 99:264-8. 2004
    ....
  20. ncbi Viral factors associated with cytokine expression during HCV/HIV co-infection
    Jason T Blackard
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Interferon Cytokine Res 27:263-9. 2007
    ..Further studies are warranted to identify noninvasive markers of liver disease for the clinical management of HCV disease, particularly when liver biopsies have not been performed or are contraindicated...
  21. ncbi Effects of HCV treatment on cytokine expression during HCV/HIV coinfection
    Jason T Blackard
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Interferon Cytokine Res 26:834-8. 2006
    ....
  22. ncbi Novel model of antigen-specific induction of bile duct injury
    James Buxbaum
    Department of Medicine, University of California, San Francisco, California 94143-0538, USA
    Gastroenterology 131:1899-906. 2006
    ..Thus, OVA BIL represents an antigen-specific animal model of inflammatory bile duct injury...
  23. ncbi Hepatitis C and alcohol: fundamental and translational research directions
    Timothy R Morgan
    Department of Medicine, Veterans Adminstration Medical Center, Long Beach, California, USA
    Alcohol Clin Exp Res 27:726-31. 2003
    ..This article summarizes the panel's deliberations and their recommendations for future research on alcohol and hepatitis C...
  24. ncbi Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant
    Jennifer E Guy
    Department of Medicine, University of California San Francisco, CA 94143-0538, USA
    Liver Transpl 11:1252-7. 2005
    ..In conclusion, recurrent PBC is not infrequent post-OLT, and ursodeoxycholic acid can be used with some benefit post-OLT. Treatment effects on long-term survival are not known...
  25. ncbi De novo malignancies following liver transplantation: a case-control study with long-term follow-up
    Francis Y Yao
    Department of Medicine, University of California San Francisco, San Francisco, CA 94143-0538, USA
    Clin Transplant 20:617-23. 2006
    ..Patients with non-skin cancer after OLT had diminished long-term survival compared with the controls. Our results differ from other reports in the high incidence of gastrointestinal malignancies with attendant poor prognosis...